08 June 2020 – GCV Digital Forum Roundup

GCV Digital Forum Roundup

Thank you to the team and all who have worked their socks off for the first GCV Digital Forum, and also the sponsors, speakers and attendees who have made it such a success. The platform will stay open for 30 days.

It was exciting to hear the industry on the GCV Leadership Society Advisory Board chaired by Young Sohn from Samsung this week share their perspectives on how communities can come closer together through these trials and create more diverse and inclusive investing environments – Samsung NEXT will share its playbook for this at the Forum and beyond.

The GCV Digital Forum has had 600 attendees from across the time zones, creating a unique network and sharing of insights yesterday and today.

Exits

Covid-19 does not seem to have done much to dampen investors’ spirits outside a few key areas and if anything, it’s accelerated what was beginning to become a comparatively stagnant M&A market. One of the biggest beneficiaries has been Intel Capital, which has already recorded exits from portfolio companies including Nysansa, CloudGenix and Moovit this year, and which is now set to exit Spot, a developer of cloud workload management software. The reported price tag is $450m, following $52m in VC funding, which looks to me like a decent return.

Thoma Bravo to execute $100m Exostar acquisition

Fibrosis drug developer Pliant Therapeutics has become the latest life sciences company to launch a successful IPO, floating at the top of its range to raise $144m after increasing the number of shares in the offering by 50%. It also represents an immediate return for Novartis Institutes for BioMedical Research, which bought $10m of shares in the flotation only to see Pliant’s share price shoot up some 50% post-IPO.

Branding Engineer gets IPO plans on track

Canada-based Repare Therapeutics is the latest drug developer to file for an initial public offering, and the precision oncology-focused company is targeting $100m in a Nasdaq IPO. The filing came just days after it raised $15m in equity funding from Bristol Myers Squibb as part of a research collaboration deal, and Repare’s existing investors also include Celgene Switzerland, a participant in its 2017 series A round.

Vroom sets $319m target for IPO

China’s stock markets look set to benefit from increasingly stringent rules in the US, and one of the country’s latest companies to file for an initial public offering is Shenzhen Yanmade Technology. It provides industrial testing equipment for flexible printed circuits and its investors include Legend Capital, which was spun off by Legend Holdings. Yanmade is looking to raise up to $98.8m and it plans to float on the Shanghai Stock Exchange’s Star Market.

Deals

On-demand ride provider Didi Chuxing has raised more than $500m for an autonomous driving subsidiary, in a round led by SoftBank’s second Vision Fund. The spinoff is the outcome of four years of driverless vehicle research from Didi and it has approval to test the technology on roads across three Chinese cities as well as California. Vision Fund was already one of Didi’s key investors, and it took part in a $150m round for the company’s bicycle rental spinoff in April.

Varo Money is one of several digital banks to spring up in the past few years, but it intends to be the first to secure a national bank charter in the United States. It has also closed a $241m series D round featuring automotive insurance specialist Progressive that hiked its overall funding to nearly $420m. Fintech has been one of the notable growth sectors in recent years, but if digital operators can start competing head to head with traditional banks we could see that growth accelerate quite quickly.

E-commerce marketplaces have been one of the more exciting investment areas in Southeast Asia in recent years, and Vietnam’s Tiki has so far been among the market’s winners. It has reportedly raised $130m in a round led by private equity firm Northstar Group, following earlier funding from the likes of CyberAgent, JD.com, Sumitomo and VNG. The company is also said to be in line for a merger with domestic competitor Sendo that would really set it up for the future.

Xiaolinggou plugs into series A round

Microbe processor Ginkgo Bioworks has increased its overall funding to nearly $790m in a $70m funding round that included strategic partner Illumina. The round also featured General Atlantic and Viking Global Investors – both of which backed a $350m vehicle called Ferment Consortium that was formed last October to invest in companies formed and spun off by Ginkgo.

University

Athira accepts $85m series B

Oxford encodes Base Genomics

Funds

Pfizer to augment VC investments with $500m

MassMutual amasses third $100m fund

No need to tell anyone that inclusion and support for black lives is on everyone’s lips right now, not least due to the recent reams of public dedications by different companies’ social media accounts. However, SoftBank is putting actual skin in the game by forming a $100m investment vehicle called the Opportunity Growth Fund specifically to back entrepreneurs and founders of colour. Not that it’s the first corporate to launch such an initiative: Comcast Ventures’ Catalyst Fund was formed in 2011 and Intel Capital put $125m into a Diversity Fund in 2015.

India-based classified listings operator Info Edge has had some success investing off its own balance sheet, particularly with Zomato and PolicyBazaar owner ETechAces, but not it’s looking to establish a dedicated corporate venturing vehicle. Info Edge Venture Fund has a $100m target, and the corporate is putting up almost half. The rest is set to come from external LPs, in what looks to be an increasingly popular model.

Real Tech goes local with latest fund


“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0

09 March 2020 – Waymo Secures $2.25bn in Initial Close of First External Round

The Big Ones

Waymo began life in Alphabet’s secretive Google X division but has now fully emerged as a standalone company, securing $2.25bn from investors including AutoNation, Magna International and Alphabet itself – an amount it said only represents the initial close of its first external round. No official word on valuation but Morgan Stanley analysts estimated its value at $105bn as of September. What this means for Alphabet portfolio company Uber, which is testing its own driverless car tech, remains to be seen.

Insurance providers Aflac, Sumitomo Life and Nürnberger have contributed to the $90m initial close of an insurance technology-focused fund being raised by UK-based venture capital firm Anthemis. Founded in 2010, Anthemis now has more than $500m in assets under management and more than 100 portfolio companies in the financial technology sector, about a third of which are insurance-related. The fund is expected to reach a final close later in 2020, according to Reuters. Aflac invested through its corporate venturing subsidiary, Aflac Global Ventures, and fellow insurer Daido Life Insurance Company is involved with the fund as an associate. Anthemis Insurance Venture Growth Fund I will invest in later-stage insurance tech businesses, beyond the traditional pre-seed to series B remit of earlier Anthemis funds.

Equinix has closed the acquisition of bare-metal automation technology provider Packet initially announced in January. The purchase price is $335m and the deal comes in the wake of just $36m in funding. That’s good news for SoftBank, which led Packet’s series A round, in addition to fellow corporate investors Dell Technologies Capital, JA Mitsui and Samsung Next.

In crossover news. Element Science has raised a sliver over $145m in a series C round that included GV, which was listed as an existing investor. Element is the developer of a wearable defibrillator for cardiac patients transferring from the hospital to their home. The round was co-led by Deerfield Healthcare and Qiming Venture Partners USA and it boosted Element’s overall funding to at least $183m. The company’s founder, president and chief executive is Uday Kumar, adjunct professor in bioengineering at Stanford University. He previously founded iRhythm Technologies, the developer of arrhythmia diagnostics technology that won the GUV Award for Exit of the Year in 2017 – and whose stock has nearly quadrupled since its IPO to give the company a current market cap of $2.6bn.

Deals

Beike Xhaofang was reported in December to be mulling over an initial public offering to raise up to $1bn, but the online property rental platform had apparently already raised more than $2.4bn in a series D-plus round punctuated by a $1bn investment from SoftBank. The round also featured existing investor Tencent and valued the company (also known as Ke.com) in excess of $14bn.

Quibi is gearing up for the launch of its short-form online streaming platform next month and has closed $750m in new financing from undisclosed new and existing investors. The new funding took Quibi’s overall equity financing to $1.75bn, the company having previously revealed Alibaba, Sony, 21st Century Fox, Walt Disney, WarnerBros, Entertainment One and WndrCo among its backers.

Immunocore has completed a $130m series B round that included WuXi AppTec’s corporate VC fund and existing investor Eli Lilly. A media report in September suggested the round was set to value the immuno-oncology molecule developer, a spinoff from MediGene, at about $625m. That sounds good until you factor in the reported $1bn valuation at which it last raised money, through a $320m round in 2015. Immunocore was spun out of biotech firm Medigene in 2008 to commercialise aspects of Avidex technology, the latter having been spun out of University of Oxford in 1999. A sister company, Adaptimmune, was formed concurrently to market other Avidex assets.

Novartis Venture Fund and Partners Innovation Fund have taken part in a $105m series B round for Akouos, which is developing precision genetic medicines to combat hearing loss. Both participated as existing backers, Novartis having been an investor since the company’s $7.5m seed round three years ago.

Immuno-oncology continues to be a strong area of life sciences, with Akrevia Therapeutics having closed a $100.5m series B round announced alongside its rebranding to Xilio Therapeutics. The round was led by Takeda Ventures and included three more corporate venturing subsidiaries of pharmaceutical firms: M Ventures, Ipsen Ventures and MRL Ventures Fund.

Pliant Therapeutics, a US-based fibrosis therapy developer based on research at University of California (UC), San Francisco, has raised $100m in a series C round led by pharmaceutical firm Novartis. Venture capital firm Third Rock Ventures formed Pliant in 2016 to advance research conducted at UC San Francisco by professors Dean Sheppard, Bill DeGrado and Hal Chapman together with associate professor Bradley Backes. The company’s now raised $207m altogether.

Thought Machine has created a cloud banking platform intended to comprehensively replace legacy banking IT systems. Its customers include Lloyds Banking Group, which has also participated in the company’s $83m series B round, making it the latest UK-based fintech developer to raise substantial funding. It is channelling the capital into its ongoing international expansion, which is currently focused on the Asia Pacific region.

Japan-based lithium-ion battery developer APB has raised ¥8bn ($74.4m) in today from investors including Keio Innovation Initiative (KII), a joint venture capital vehicle for Keio University and securities brokerage Nomura Holdings. Industrial, mining and petroleum group JXTG Holdings took part through subsidiary JXTG Innovation Partners while coal chemistry technology provider JFE Chemical, construction firm Obayashi Corporation, textile manufacturer Teijin and industrial technology producers Nagase & Co and Yokogawa Electric invested directly. The company was founded in October 2018 through a partnership between KII and Keio University professor Hideaki Horie.

Quantum computing technology developer Rigetti Computing is well on the way to its next round, having accumulated $71m for a targeted close of $83.9m, according to a securities filing. The company has now disclosed a total of $190m in funding and its earlier backers include Bloomberg Beta, which invested in its $24m series A round.

Funds

Mandatum Life, the insurance subsidiary of financial services group Sampo, has contributed to the €30m ($32.6m) first close for an insurance technology-focused fund formed by Finland-based venture capital firm Innovestor. B2B Industrial Technology Fund has an expected ceiling of €100m and its other limited partners include unnamed institutional investors, family offices and individual backers. It expects to begin investing as early as the second quarter of 2020.

Exits

Accolade, the developer of a digital concierge designed to help users navigate the healthcare benefits system, has filed for a $100m initial public offering that will give corporate backers Comcast, Humana, McKesson Ventures and Independence Health Group the opportunity to exit. The company has raised more than $194m in financing since being founded in 2007.

Oric Pharmaceuticals is the latest oncology therapeutics developer to file for an initial public offering and is targeting $86.3m in the IPO. Taiho, Memorial Sloan Kettering Cancer Center and Hartford HealthCare are in line for exits, having all contributed to a $55.7m series D round last August that pushed Oric’s total funding past $175m.

Artificial intelligence chip producer Cambricon Technologies has applied to list on the Shanghai Stock Exchange’s Star Market, in an initial public offering that will give corporate backers Alibaba, Lenovo, Zhongke Tuling Century Beijing Technology and iFlytek a chance to exit. The company has raised at least $200m in funding and was valued at $2.5bn in its last round, a 2018 series B.


“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0